| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results.
|
Blood
|
2006
|
7.30
|
|
2
|
Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.
|
N Engl J Med
|
2014
|
5.37
|
|
3
|
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs.
|
Mayo Clin Proc
|
2015
|
4.70
|
|
4
|
Gene expression changes associated with progression and response in chronic myeloid leukemia.
|
Proc Natl Acad Sci U S A
|
2006
|
3.70
|
|
5
|
The genomic landscape of hypodiploid acute lymphoblastic leukemia.
|
Nat Genet
|
2013
|
3.43
|
|
6
|
High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia.
|
J Clin Oncol
|
2012
|
2.13
|
|
7
|
A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia.
|
Blood
|
2012
|
2.11
|
|
8
|
Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710.
|
Blood
|
2010
|
2.05
|
|
9
|
Adult acute lymphoblastic leukemia: concepts and strategies.
|
Cancer
|
2010
|
1.78
|
|
10
|
Phase 3 randomized, placebo-controlled, double-blind study of high-dose continuous infusion cytarabine alone or with laromustine (VNP40101M) in patients with acute myeloid leukemia in first relapse.
|
Blood
|
2009
|
1.72
|
|
11
|
A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies.
|
Clin Cancer Res
|
2008
|
1.63
|
|
12
|
Treatment-influenced associations of PML-RARα mutations, FLT3 mutations, and additional chromosome abnormalities in relapsed acute promyelocytic leukemia.
|
Blood
|
2012
|
1.61
|
|
13
|
Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909.
|
J Clin Oncol
|
2009
|
1.61
|
|
14
|
A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia.
|
Leuk Lymphoma
|
2009
|
1.58
|
|
15
|
Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease.
|
Leuk Lymphoma
|
2010
|
1.55
|
|
16
|
Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions.
|
Blood
|
2011
|
1.55
|
|
17
|
Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study.
|
Lancet Oncol
|
2012
|
1.54
|
|
18
|
Arsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotype.
|
Leuk Lymphoma
|
2014
|
1.53
|
|
19
|
Recombinant interleukin-2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: results from Cancer and Leukemia Group B 19808.
|
Cancer
|
2013
|
1.48
|
|
20
|
Performance status and comorbidity predict transplant-related mortality after allogeneic hematopoietic cell transplantation.
|
Biol Blood Marrow Transplant
|
2006
|
1.44
|
|
21
|
P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808.
|
Blood
|
2010
|
1.41
|
|
22
|
Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity.
|
J Clin Oncol
|
2005
|
1.33
|
|
23
|
NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on Disease-Specific Methods and Strategies for Monitoring Relapse following Allogeneic Stem Cell Transplantation. Part I: Methods, acute leukemias, and myelodysplastic syndromes.
|
Biol Blood Marrow Transplant
|
2010
|
1.23
|
|
24
|
Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial.
|
Clin Cancer Res
|
2013
|
1.19
|
|
25
|
Paucity of HLA-identical unrelated donors for African-Americans with hematologic malignancies: the need for new donor options.
|
Biol Blood Marrow Transplant
|
2008
|
1.18
|
|
26
|
Granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML).
|
Blood
|
2009
|
1.18
|
|
27
|
Progress in the treatment of adults with acute lymphoblastic leukemia.
|
Curr Opin Hematol
|
2008
|
1.09
|
|
28
|
Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia.
|
Blood
|
2002
|
1.06
|
|
29
|
Burkitt lymphoma/leukemia: improving prognosis.
|
Clin Lymphoma Myeloma
|
2009
|
0.99
|
|
30
|
BK virus infection is associated with hematuria and renal impairment in recipients of allogeneic hematopoetic stem cell transplants.
|
Biol Blood Marrow Transplant
|
2009
|
0.99
|
|
31
|
Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia.
|
Invest New Drugs
|
2008
|
0.99
|
|
32
|
Phase 1 multicenter study of vincristine sulfate liposomes injection and dexamethasone in adults with relapsed or refractory acute lymphoblastic leukemia.
|
Cancer
|
2009
|
0.99
|
|
33
|
Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence.
|
Leuk Lymphoma
|
2009
|
0.99
|
|
34
|
Pretreatment C-reactive protein is a predictor for outcomes after reduced-intensity allogeneic hematopoietic cell transplantation.
|
Biol Blood Marrow Transplant
|
2008
|
0.98
|
|
35
|
Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia.
|
Br J Haematol
|
2013
|
0.98
|
|
36
|
A phase II study of continuous infusion homoharringtonine and cytarabine in newly diagnosed patients with chronic myeloid leukemia: CALGB study 19804.
|
Cancer Chemother Pharmacol
|
2008
|
0.98
|
|
37
|
FLT3 mutation status is a predictor of early death in pediatric acute promyelocytic leukemia: a report from the Children's Oncology Group.
|
Pediatr Blood Cancer
|
2012
|
0.95
|
|
38
|
A phase I biological study of MG98, an oligodeoxynucleotide antisense to DNA methyltransferase 1, in patients with high-risk myelodysplasia and acute myeloid leukemia.
|
Clin Cancer Res
|
2008
|
0.95
|
|
39
|
Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic malignancies.
|
J Clin Oncol
|
2004
|
0.94
|
|
40
|
Histone deacetylase inhibitor romidepsin has differential activity in core binding factor acute myeloid leukemia.
|
Clin Cancer Res
|
2008
|
0.94
|
|
41
|
Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy.
|
Br J Haematol
|
2014
|
0.93
|
|
42
|
A Phase II study of Bcl-2 antisense (oblimersen sodium) combined with gemtuzumab ozogamicin in older patients with acute myeloid leukemia in first relapse.
|
Leuk Res
|
2006
|
0.93
|
|
43
|
REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemia.
|
Br J Haematol
|
2014
|
0.93
|
|
44
|
Umbilical cord blood transplantation supported by third-party donor cells: rationale, results, and applications.
|
Biol Blood Marrow Transplant
|
2012
|
0.93
|
|
45
|
Phase I-II study of clofarabine-melphalan-alemtuzumab conditioning for allogeneic hematopoietic cell transplantation.
|
Biol Blood Marrow Transplant
|
2011
|
0.92
|
|
46
|
NCI first international workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on disease-specific methods and strategies for monitoring relapse following allogeneic stem cell transplantation. part II: chronic leukemias, myeloproliferative neoplasms, and lymphoid malignancies.
|
Biol Blood Marrow Transplant
|
2010
|
0.91
|
|
47
|
Gene mutations, epigenetic dysregulation, and personalized therapy in myeloid neoplasia: are we there yet?
|
Semin Oncol
|
2011
|
0.90
|
|
48
|
T-cell-depleted allogeneic transplant without donor leukocyte infusions results in excellent long-term survival in patients with multiply relapsed Lymphoma. Predictors for survival after transplant relapse.
|
Leuk Lymphoma
|
2010
|
0.87
|
|
49
|
Assaying Bcr-Abl kinase activity and inhibition in whole cell extracts by phosphorylation of substrates immobilized on agarose beads.
|
Anal Biochem
|
2005
|
0.86
|
|
50
|
Detection of minimal residual disease following induction immunochemotherapy predicts progression free survival in mantle cell lymphoma: final results of CALGB 59909.
|
Haematologica
|
2011
|
0.86
|
|
51
|
Clinical trials in adult AML.
|
Clin Adv Hematol Oncol
|
2009
|
0.84
|
|
52
|
Successful allogeneic transplantation of patients with suspected prior invasive mold infection.
|
Leuk Lymphoma
|
2007
|
0.84
|
|
53
|
Investigating bias in psychotherapy with BDSM clients.
|
J Homosex
|
2006
|
0.84
|
|
54
|
Autologous transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia achieves outcomes similar to allogeneic transplantation: results of CALGB Study 10001 (Alliance).
|
Haematologica
|
2013
|
0.83
|
|
55
|
Immune reconstitution after combined haploidentical and umbilical cord blood transplant.
|
Leuk Lymphoma
|
2013
|
0.82
|
|
56
|
Allogeneic stem cell transplantation with alemtuzumab-based conditioning for patients with advanced chronic myelogenous leukemia.
|
Leuk Lymphoma
|
2009
|
0.82
|
|
57
|
Clofarabine-associated acute kidney injury in patients undergoing hematopoietic stem cell transplant.
|
Leuk Lymphoma
|
2014
|
0.82
|
|
58
|
Children, adolescents, and young adults with leukemia: the empty half of the glass is growing.
|
J Clin Oncol
|
2012
|
0.82
|
|
59
|
Durable molecular remissions with a single cycle of timed sequential consolidation chemotherapy in acute promyelocytic leukemia.
|
Am J Hematol
|
2005
|
0.81
|
|
60
|
Minimal residual disease in acute myeloid leukemia--current status and future perspectives.
|
Curr Hematol Malig Rep
|
2015
|
0.80
|
|
61
|
Actinomycosis presenting as an oral ulcer in a neutropenic patient.
|
South Med J
|
2002
|
0.80
|
|
62
|
A phase I and pharmacodynamic study of the histone deacetylase inhibitor belinostat plus azacitidine in advanced myeloid neoplasia.
|
Invest New Drugs
|
2014
|
0.80
|
|
63
|
An integrated genomic approach to the assessment and treatment of acute myeloid leukemia.
|
Semin Oncol
|
2011
|
0.79
|
|
64
|
Expanded indications for allogeneic stem cell transplantation in patients with myeloid malignancies.
|
Curr Opin Hematol
|
2013
|
0.79
|
|
65
|
Influence of related donor age on outcomes after peripheral blood stem cell transplantation.
|
Cytotherapy
|
2012
|
0.79
|
|
66
|
High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902.
|
Leuk Res
|
2010
|
0.78
|
|
67
|
Phase II study of autologous transplantation with interleukin-2-incubated peripheral blood stem cells and posttransplantation interleukin-2 in relapsed or refractory non-Hodgkin lymphoma.
|
Biol Blood Marrow Transplant
|
2004
|
0.78
|
|
68
|
Successful autologous stem cell collection in patients with chronic myeloid leukemia in complete cytogenetic response, with quantitative measurement of BCR-ABL expression in blood, marrow, and apheresis products.
|
Leuk Lymphoma
|
2008
|
0.78
|
|
69
|
Preface: acute lymphoblastic leukemia--quo vadis?
|
Hematol Oncol Clin North Am
|
2009
|
0.77
|
|
70
|
Irreversible myelosuppression after fludarabine-melphalan conditioning: observations in patients with graft rejection.
|
Blood
|
2004
|
0.76
|
|
71
|
Screening for clonal hematopoiesis as a predictive marker for development of therapy-related myeloid neoplasia (t-MN) following neoadjuvant therapy for breast cancer: a Southwest Oncology Group study (S0012).
|
Breast Cancer Res Treat
|
2010
|
0.76
|
|
72
|
High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk acute myeloid leukemia (AML).
|
Leuk Lymphoma
|
2012
|
0.76
|
|
73
|
Treatment of therapy-related myeloid neoplasms with high-dose cytarabine/mitoxantrone followed by hematopoietic stem cell transplant.
|
Leuk Lymphoma
|
2010
|
0.76
|
|
74
|
RCSD1-ABL2 fusion resulting from a complex chromosomal rearrangement in high-risk B-cell acute lymphoblastic leukemia.
|
Leuk Lymphoma
|
2014
|
0.76
|
|
75
|
Phase 1 trial of linifanib (ABT-869) in patients with refractory or relapsed acute myeloid leukemia.
|
Leuk Lymphoma
|
2012
|
0.76
|
|
76
|
A pharmacogenetic study of aldehyde oxidase I in patients treated with XK469.
|
Pharmacogenet Genomics
|
2014
|
0.75
|
|
77
|
Treatment of the chronic phase of chronic myeloid leukemia with an intermittent schedule of recombinant interferon alfa-2b and cytarabine: results from CALGB study 9013.
|
Leuk Lymphoma
|
2003
|
0.75
|
|
78
|
Looking toward the future: novel strategies based on molecular pathogenesis of acute lymphoblastic leukemia.
|
Hematol Oncol Clin North Am
|
2009
|
0.75
|
|
79
|
Inclusion of Adolescents and Young Adults in Cancer Clinical Trials.
|
Semin Oncol Nurs
|
2015
|
0.75
|
|
80
|
Progressive transformation of germinal centers. Report of 2 cases and review of the literature.
|
Acta Haematol
|
2002
|
0.75
|
|
81
|
Approaches to treatment for acute lymphoblastic leukemia in adolescents and young adults.
|
Curr Hematol Malig Rep
|
2008
|
0.75
|
|
82
|
Counterpoint: Standard vs Investigational Agents as Upfront Treatment for High-Risk AML.
|
Oncology (Williston Park)
|
2017
|
0.75
|